These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 36011850)

  • 1. Determinants of Survival of HIV Patients Receiving Dolutegravir: A Prospective Cohort Study in Conflict-Affected Bunia, Democratic Republic of Congo.
    Buju RT; Akilimali PZ; Tran NT; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
    Int J Environ Res Public Health; 2022 Aug; 19(16):. PubMed ID: 36011850
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incidence and Predictors of Loss to Follow Up among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.
    Buju RT; Akilimali PZ; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
    Int J Environ Res Public Health; 2022 Apr; 19(8):. PubMed ID: 35457498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictors of Viral Non-Suppression among Patients Living with HIV under Dolutegravir in Bunia, Democratic Republic of Congo: A Prospective Cohort Study.
    Buju RT; Akilimali PZ; Kamangu EN; Mesia GK; Kayembe JMN; Situakibanza HN
    Int J Environ Res Public Health; 2022 Jan; 19(3):. PubMed ID: 35162109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Viral Load Status Before Switching to Dolutegravir-Containing Antiretroviral Therapy and Associations With Human Immunodeficiency Virus Treatment Outcomes in Sub-Saharan Africa.
    Romo ML; Edwards JK; Semeere AS; Musick BS; Urassa M; Odhiambo F; Diero L; Kasozi C; Murenzi G; Lelo P; Wyka K; Kelvin EA; Sohn AH; Wools-Kaloustian KK; Nash D;
    Clin Infect Dis; 2022 Sep; 75(4):630-637. PubMed ID: 34893813
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viral suppression and HIV-1 drug resistance 1 year after pragmatic transitioning to dolutegravir first-line therapy in Malawi: a prospective cohort study.
    Schramm B; Temfack E; Descamps D; Nicholas S; Peytavin G; Bitilinyu-Bangoh JE; Storto A; Lê MP; Abdi B; Ousley J; Kalua T; Calvez V; Jahn A; Marcelin AG; Szumilin E
    Lancet HIV; 2022 Aug; 9(8):e544-e553. PubMed ID: 35905753
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disclosure of HIV status and its impact on the loss in the follow-up of HIV-infected patients on potent anti-retroviral therapy programs in a (post-) conflict setting: A retrospective cohort study from Goma, Democratic Republic of Congo.
    Akilimali PZ; Musumari PM; Kashala-Abotnes E; Kayembe PK; Lepira FB; Mutombo PB; Tylleskar T; Ali MM
    PLoS One; 2017; 12(2):e0171407. PubMed ID: 28170410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
    Gagliardini R; Gianotti N; Maggiolo F; Cozzi-Lepri A; Antinori A; Nozza S; Lapadula G; De Luca A; Mussini C; Gori A; Saracino A; Andreoni M; Monforte AD;
    Int J Antimicrob Agents; 2021 Oct; 58(4):106406. PubMed ID: 34293454
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of switching to dolutegravir plus lamivudine versus continuing triple antiretroviral therapy in virologically suppressed adults with HIV at 48 weeks (DOLAM): a randomised non-inferiority trial.
    Rojas J; de Lazzari E; Negredo E; Domingo P; Tiraboschi J; Ribera E; Abdulghani N; Puig J; Mateo MG; Podzamczer D; Gutierrez MM; Paredes R; Clotet B; Gatell JM; Blanco JL; Martínez E;
    Lancet HIV; 2021 Aug; 8(8):e463-e473. PubMed ID: 34358497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bictegravir combined with emtricitabine and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection: week 96 results from a randomised, double-blind, multicentre, phase 3, non-inferiority trial.
    Wohl DA; Yazdanpanah Y; Baumgarten A; Clarke A; Thompson MA; Brinson C; Hagins D; Ramgopal MN; Antinori A; Wei X; Acosta R; Collins SE; Brainard D; Martin H
    Lancet HIV; 2019 Jun; 6(6):e355-e363. PubMed ID: 31068270
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dolutegravir with emtricitabine and tenofovir alafenamide or tenofovir disoproxil fumarate versus efavirenz, emtricitabine, and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection (ADVANCE): week 96 results from a randomised, phase 3, non-inferiority trial.
    Venter WDF; Sokhela S; Simmons B; Moorhouse M; Fairlie L; Mashabane N; Serenata C; Akpomiemie G; Masenya M; Qavi A; Chandiwana N; McCann K; Norris S; Chersich M; Maartens G; Lalla-Edward S; Vos A; Clayden P; Abrams E; Arulappan N; Hill A
    Lancet HIV; 2020 Oct; 7(10):e666-e676. PubMed ID: 33010240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dolutegravir as maintenance monotherapy for HIV (DOMONO): a phase 2, randomised non-inferiority trial.
    Wijting I; Rokx C; Boucher C; van Kampen J; Pas S; de Vries-Sluijs T; Schurink C; Bax H; Derksen M; Andrinopoulou ER; van der Ende M; van Gorp E; Nouwen J; Verbon A; Bierman W; Rijnders B
    Lancet HIV; 2017 Dec; 4(12):e547-e554. PubMed ID: 29107562
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy and safety of first-line antiretroviral therapy for the treatment of HIV infection: a systematic review and network meta-analysis.
    Kanters S; Vitoria M; Doherty M; Socias ME; Ford N; Forrest JI; Popoff E; Bansback N; Nsanzimana S; Thorlund K; Mills EJ
    Lancet HIV; 2016 Nov; 3(11):e510-e520. PubMed ID: 27658869
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Durability of Dolutegravir-Based Regimens: A 5-Year Prospective Observational Study.
    Taramasso L; De Vito A; Ricci ED; Orofino G; Squillace N; Menzaghi B; Molteni C; Gulminetti R; De Socio GV; Pellicanò GF; Sarchi E; Celesia BM; Calza L; Rusconi S; Valsecchi L; Martinelli CV; Cascio A; Maggi P; Vichi F; Angioni G; Guadagnino G; Cenderello G; Dentone C; Bandera A; Falasca K; Bonfanti P; Di Biagio A; Madeddu G;
    AIDS Patient Care STDS; 2021 Sep; 35(9):342-353. PubMed ID: 34524918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Viral suppression after transition from nonnucleoside reverse transcriptase inhibitor- to dolutegravir-based antiretroviral therapy: A prospective cohort study in Lesotho (DO-REAL study).
    Brown JA; Nsakala BL; Mokhele K; Rakuoane I; Muhairwe J; Urda L; Amstutz A; Tschumi N; Klimkait T; Labhardt ND
    HIV Med; 2022 Mar; 23(3):287-293. PubMed ID: 34632682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Factors of Mortality among Adult Patients on Antiretroviral Therapy in India: A Hospital Based Retrospective Cohort Study.
    Joseph N; Sinha U; Tiwari N; Ghosh P; Sindhu P
    Biomed Res Int; 2019; 2019():1419604. PubMed ID: 30805359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Determinants of survival in HIV patients receiving antiretroviral therapy in Goma, Democratic Republic of Congo].
    Akilimali PZ; Mutombo PB; Kayembe PK; Kaba DK; Mapatano MA
    Rev Epidemiol Sante Publique; 2014 Jun; 62(3):201-6. PubMed ID: 24880569
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of Survival among Adult Ethiopian Patients in the National ART Program at Seven University Teaching Hospitals: A Prospective Cohort Study.
    Fekade D; Weldegebreal T; Teklu AM; Damen M; Abdella S; Baraki N; Belayhun B; Berhan E; Kebede A; Assefa Y
    Ethiop J Health Sci; 2017 Feb; 27(Suppl 1):63-71. PubMed ID: 28465654
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of dolutegravir-based regimens in advanced HIV-infected naïve patients: results from a multicenter cohort study.
    Rossetti B; Baldin G; Sterrantino G; Rusconi S; De Vito A; Giacometti A; Gagliardini R; Colafigli M; Capetti A; d'Ettorre G; Celani L; Lagi F; Ciccullo A; De Luca A; Di Giambenedetto S; Madeddu G
    Antiviral Res; 2019 Sep; 169():104552. PubMed ID: 31283942
    [TBL] [Abstract][Full Text] [Related]  

  • 19. ODYSSEY clinical trial design: a randomised global study to evaluate the efficacy and safety of dolutegravir-based antiretroviral therapy in HIV-positive children, with nested pharmacokinetic sub-studies to evaluate pragmatic WHO-weight-band based dolutegravir dosing.
    Moore CL; Turkova A; Mujuru H; Kekitiinwa A; Lugemwa A; Kityo CM; Barlow-Mosha LN; Cressey TR; Violari A; Variava E; Cotton MF; Archary M; Compagnucci A; Puthanakit T; Behuhuma O; Saϊdi Y; Hakim J; Amuge P; Atwine L; Musiime V; Burger DM; Shakeshaft C; Giaquinto C; Rojo P; Gibb DM; Ford D;
    BMC Infect Dis; 2021 Jan; 21(1):5. PubMed ID: 33446115
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting.
    d'Arminio Monforte A; Cozzi-Lepri A; Di Biagio A; Marchetti G; Lo Caputo S; Rusconi S; Gianotti N; Mazzotta V; Mazzarello G; Costantini A; Castagna A; Antinori A;
    J Antimicrob Chemother; 2019 May; 74(5):1363-1367. PubMed ID: 30698801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.